A similar pan‐cancer analysis, which lacked access to detailed clinical data, demonstrated that the prevalence of CDK12 genomic alterations was 1.1% across all cancer types, with mutations most frequently seen in prostate, gastrointestinal, and gynecologic malignancies.7 The gene discussed is CDK12; the disease is cancer.